Gene therapy during heart bypass surgery to improve blood flow
Part of Heart & circulation clinical trials.
This study tests a gene therapy given during heart bypass surgery to help grow new blood vessels in the heart. It aims to improve blood flow to areas that bypass surgery alone can't fully fix.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You need to be scheduled for coronary artery bypass surgery (CABG) and have a heart pumping strength between 25% and 50%.
- You need to have blockages in your heart arteries that the surgeon expects will be hard to fully bypass.
- You must not have had a heart attack or stroke in the last 60 days.
- You cannot have a pacemaker, a recent cancer diagnosis, or certain other serious health conditions.
- You need to be willing to use reliable birth control for 6 months after the procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special balloon coated with medicine to treat blocked small arteries in the heart. It may help people who have new blockages and are getting a procedure to open those arteries.
This trial tests a drug called EA-230 that may help people recover faster after heart bypass surgery. If you are having planned bypass surgery, this drug might shorten your hospital stay.
This trial tests a new gene therapy (XC001) delivered through a thin tube into your heart's blood vessels. It aims to grow new blood vessels to relieve chest pain in people with chronic angina who have no other treatment options.
This study tests a new treatment using donor stem cells injected into the heart during scheduled bypass surgery. The goal is to see if these cells help improve heart function in people with heart failure due to blocked arteries and a weak heart pump.
This study tests a new way to connect a bypass graft during heart bypass surgery for people with blocked heart arteries. The goal is to see if the new graft can be safely placed and works well enough to improve outcomes compared with the standard approach.
This trial tests a lab-grown blood vessel that is designed to be used as an extra bypass graft during heart surgery. It aims to offer a safe alternative for patients who need multiple bypasses, and the new vessel may help improve long-term blood flow.
Hear when a new Coronary Artery Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.